TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15541252
Drug: Eptifibatide (glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (glycoprotein IIb/IIIa platelet receptor inhibitor) for 24 hours
Study: 11941231
Drug: Amukine 0.06%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amukine 0.06% solution
Study: 11941231
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine (Bétadine) 5% solution
Study: 10230996
Drug: Antiparkinsonian medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiparkinsonian medications in PD-F patients
Study: 14652
Drug: Carpipramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carpipramine (3 X 100 mg daily for 43 days)
Study: 30977382
Drug: Lycra® gauntlets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycra® gauntlets for eight hours daily for eight weeks, plus usual rehabilitation (n=27)
Study: 23443830
Drug: basic combination
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic combination (white bread, milk, spreads, juice, ice-cream)
Study: 11773207
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone + Testosterone (GH + T)
Study: 11773207
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) + HRT
Study: 9561680
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment (more prevalent in CyA-treated patients)
Study: 2722224
Drug: Oral hydrocortisone
Normalized name: hydrocortisone Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrocortisone (200 mg/day for 1 week)
Study: 55717
Drug: Diazoxide 5
Normalized name: diazoxide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide 5 mg/kg/day for 7 days with insulin
Study: 55717
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with insulin
Study: 25298894
Drug: Topical menthol
Normalized name: menthol Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical menthol (Biofreeze)
Study: 25298894
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel with a menthol scent)
Study: 10411810
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy in addition to antimicrobial agents
Study: 10411810
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy alone
Study: 3886395
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg plus codeine 30 mg
Study: 25335944
Drug: Proactive +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive + 4 weeks of medication (Counselor‐initiated intervention)
Study: 25335944
Drug: Reactive +
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive + 2 weeks of medication (Participant‐initiated intervention)
Study: 15248204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 3 DMARDs (methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone)
Study: 12587686
Drug: Bromelain 200
Normalized name: Bromelain
DrugBank: Bromelains (DB13281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain 200 mg per day
Study: 12587686
Drug: Bromelain 400
Normalized name: ARNICA MONTANA FLOWER 50 mg / STEM BROMELAIN 400 mg / SODIUM ASCORBATE 120 mg / HESPERIDIN METHYLCHALCONE 25 mg / RUTIN 50 mg / DIOSMIN 200 mg / HESPERIDIN 25 mg / ZINC PICOLINATE 10 mg ORAL TABLET [Bruselix Bruising]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromelain 400 mg per day
Study: 9535138
Drug: Newer blood-pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer blood-pressure-lowering drugs (such as angiotensin converting enzyme inhibitors and calcium antagonists)
Study: 9535138
Drug: Newer blood-pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer blood-pressure-lowering treatments
Study: 9535138
Drug: Older classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older classes of blood-pressure-lowering drugs
Study: 7640499
Drug: Lappaconitine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lappaconitine 4 ml
Study: 7640499
Drug: Lappaconitine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lappaconitine 8 ml
Study: 7640499
Drug: Lappaconitine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lappaconitine 12 ml
Study: 7640499
Drug: 0.9% NS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NS 6 ml (Control)
Study: 7640499
Drug: Morphine 2
Normalized name: apomorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2 mg (Control)
Study: 1325010
Drug: Reduced doses
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced doses of lisinopril and sustained release verapamil (group III)
Study: 1325010
Drug: Lisinopril alone
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril alone (group I)
Study: 26963073
Drug: Standard nonoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nonoperative treatment
Study: 21699645
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg/day)
Study: 17671533
Drug: Postoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative chemoradiation (surgery followed by radiation therapy at 50Gy/5 weeks, 2Gy/fraction, 5 days/week) plus chemotherapy (Leucovorin 300mg/m2 followed by 5-FU 350mg/m2)
Study: 17671533
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (46Gy/4.5 weeks, 2Gy/fraction, 5 days/week) followed by surgery +/- postoperative chemotherapy
Study: 11202417
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg gossypol
Study: 11202417
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg gossypol
Study: 2454358
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg b.i.d.)
Study: 29648642
Drug: Frontal cerebral
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frontal cerebral thermal therapy (maintained at 14‐16°C)
Study: 24745696
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 mg/kg, every 3 weeks for 1 year
Study: 17656661
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intraarterial approach to recanalization
Study: 11919227
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5-FU-based)
Study: 3066856
Drug: Postoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiotherapy combined with CCNU chemotherapy (100 mg/sq m every 6-8 weeks)
Study: 30371518
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (neuroma excision and burying into muscle)
Study: 27922029
Drug: Eluxadoline 75
Normalized name: eluxadoline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline 75 mg BID
Study: 27922029
Drug: Eluxadoline 100
Normalized name: eluxadoline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline 100 mg BID
Study: 26547229
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without treatment for edema
Study: 16784956
Drug: DHEA (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (100-400 mg/d)
Study: 9420016
Drug: Combination 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination 5‐FU plus leucovorin (LV)
Study: 9420016
Drug: Monthly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly schedule of 5‐FU/LV (200 mg/m2)
Study: 9420016
Drug: Weekly schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly schedule of 5‐FU/LV (high-dose LV)
Study: 9420016
Drug: Racemic commercial
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic commercial formulation of LV
Study: 9420016
Drug: Sequential methotrexate/5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential methotrexate/5‐FU
Study: 9420016
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion schedules of 5‐FU
Study: 8305958
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) at a dose of 400 mg/kg
Study: 31894236
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone enanthate/week
Study: 22711752
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg b.i.d.
Study: 22863658
Drug: DTaP-IPV-Hep B-PRP-T
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-Hep B-PRP-T vaccine
Study: 22863658
Drug: Licensed hexavalent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed hexavalent control vaccine (Infanrix™ hexa)
Study: 19423470
Drug: Sequential intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily
Study: 19423470
Drug: i.v. ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ceftriaxone 2 g once daily plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily
Study: 19423470
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (moxifloxacin and ceftriaxone/metronidazole)
Study: 18270944
Drug: Intrathecal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal meperidine (15 mg) plus 75 mg of hyperbaric lidocaine 5%
Study: 18270944
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline plus 75 mg of hyperbaric lidocaine 5%
Study: 11552922
Drug: rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 10 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Study: 11552922
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Study: 11552922
Drug: rabeprazole 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 40 mg plus amoxicillin 750 mg and clarithromycin 200 mg
Study: 7946364
Drug: Rocuronium 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 600 micrograms/kg intubation dose
Study: 7946364
Drug: Maintenance doses
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance doses of rocuronium
Study: 21663949
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg plus Ezetimibe 10 mg daily
Study: 23332608
Drug: Evidence-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based intervention (cognitive behavioral therapy, psychotropic medication or both)
Study: 18926434
Drug: Conivaptan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan (20 mg loading dose followed by 2 successive 24-hour continuous infusions of 40, 80, or 120 mg/d)
Study: 8973993
Drug: Dextroamphetamine 5
Normalized name: dextroamphetamine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 5 mg
Study: 8973993
Drug: Dextroamphetamine 10
Normalized name: dextroamphetamine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 10 mg
Study: 9617982
Drug: Dextroamphetamine 20
Normalized name: dextroamphetamine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 20 mg
Study: 1456384
Drug: New slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New slow-release preparation of valproic acid (SR-VPA)
Study: 1456384
Drug: Conventional preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional preparation of valproic acid (C-VPA)
Study: 29630570
Drug: Controlled Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Active Motion (CAM) therapy
Study: 29630570
Drug: Continuous Passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Passive Motion (CPM) therapy
Study: 26352863
Drug: Melatonin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1 or 3 mg nightly)
Study: 25130678
Drug: Atorvastatin (20mg/d)
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (20mg/d)
Study: 22787067
Drug: Full-dose polycap
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose polycap (plus K(+) supplementation)
Study: 22787067
Drug: Low-dose polycap
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose polycap
Study: 20150769
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy plus radiotherapy
Study: 15316509
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin sodium (5000 IU/mL)
Study: 9602202
Drug: rhEPO 750
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 750 IU/kg/week (low-dose group)
Study: 9602202
Drug: rhEPO 1500
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO 1500 IU/kg/week (high-dose group)
Study: 8030684
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (400 micrograms IV four times) and betamethasone (5 mg IM four times)
Study: 2810410
Drug: Clindamycin dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin dosed at 1,200 mg every 12 hours
Study: 2810410
Drug: High-dose amikacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amikacin (11 mg/kg)
Study: 30016770
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (LOLA) 6-9 g/d for 12 weeks
Study: 29727385
Drug: L-ornithine L-aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine L-aspartate (LOLA)
Study: 26503196
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose interferon alfa-2b (iHDI) 20 MIU/m2 administered intravenously 5 days a week for 4 weeks then repeated every 4 months
Study: 26503196
Drug: Standard high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-dose interferon alfa-2b (HDI)
Study: 19030864
Drug: Manual lymphatic
Normalized name: PINPOINT Lymphatics Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymphatic drainage (MLD) therapy
Study: 19030864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonsteroidal anti-inflammatory drug, physical therapy, and therapeutic exercise program)
Study: 16127567
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF; n = 52)
Study: 16127567
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz; n = 52)
Study: 16127567
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg q.d.), tetracycline (500 mg q.i.d.), and furazolidone (200 mg t.i.d.) for 7 days (LTF)
Study: 16127567
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week, plus azithromycin (500 mg q.d.) for the first 3 days (LAAz)
Study: 10660161
Drug: Conventional biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional biological aortic valve replacement (Carpentier‐Edwards, n = 74)
Study: 1971641
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g)
Study: 1971641
Drug: Capsule medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule medium
Study: 24149990
Drug: Conventional ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ultrasound therapy
Study: 27386814
Drug: Game-based constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Game-based constraint-induced movement therapy (CIMT)
Study: 23413135
Drug: l-arginine aspartate
DrugBank: Arginine aspartate (DB15993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine aspartate 8 g combined with 200 mg of adenosine monophosphate (AA)
Study: 19954529
Drug: Nitazoxanide 200
Normalized name: nitazoxanide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide 200 mg bid for 28 days (1-3 years old) or 400 mg bid for 28 days (4-11 years old)
Study: 17382741
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil for 6 weeks
Study: 17382741
Drug: 5/20 mg
Normalized name: Azor 5/20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/20 mg tadalafil for 12 weeks
Study: 17382741
Drug: 5/20 mg
Normalized name: Azor 5/20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/20 mg tadalafil with placebo run-in for 12 weeks
Study: 17382741
Drug: 5/20 mg
Normalized name: Azor 5/20 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/20 mg tadalafil for sexually active men with erectile dysfunction
Study: 3169109
Drug: Oral diltiazem
Normalized name: diltiazem Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diltiazem 120 mg
Study: 28756068
Drug: Iclaprim 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim 0.8 mg/kg IV q12h
Study: 28756068
Drug: Iclaprim 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iclaprim 1.2 mg/kg IV q8h
Study: 28756068
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g IV q12h
Study: 26164092
Drug: Multi-component intervention
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component intervention (Group A) including pedometers, website for step registration, physical activity on prescription, motivational interviewing (10 occasions), and group consultations (12 occasions)
Study: 20069307
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg bupivacaine alone
Study: 20069307
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg bupivacaine, 25 mg mepivacaine and 0.0125 mg epinephrine
Study: 18821691
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg every 4 weeks for 24 weeks
Study: 10353583
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (1600 microg four times daily)
Study: 7728627
Drug: Active chiropractic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active chiropractic spinal manipulative treatment
Study: 7728627
Drug: Sham chiropractic
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham chiropractic spinal manipulative treatment
Study: 2045756
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg purified caffeine
Study: 30916531
Drug: Afferent electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Afferent electrical stimulation with mirror therapy
Study: 30916531
Drug: Sham afferent
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham afferent electrical stimulation with sham mirror therapy
Study: 21354681
Drug: Desmopressin acetate,
Normalized name: Desmopressin Acetate, 0.2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin acetate, 0.3 μg/kg
Study: 3895365
Drug: Bornaprine 8
Normalized name: bornaprine
DrugBank: Bornaprine (DB13619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprine 8 mg/die
Study: 27594130
Drug: Oral direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral direct factor Xa inhibitors
Study: 20080036
Drug: Risperidone (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-6 mg/day)
Study: 15890074
Drug: Single dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosage of memantine
Study: 15890074
Drug: Ascending dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dosage of memantine over 8 days
Study: 10073852
Drug: COER-24 verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER-24 verapamil 240 mg titrated to 480 mg at bedtime (n = 173)
Study: 10073852
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg titrated to 10 mg/day (n = 149)
Study: 10073852
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg plus atenolol 50 mg/day in the A.M. (n = 154)
Study: 2390587
Drug: Mastectomy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastectomy treatment